Oligo Factory

02/23/2024

When you're doing pre-clinical oligo development, quality is critical. At Oligo Factory, we have rigorous quality assurance measures in place for both RUO and GMP oligo production. Our skilled team works together to ensure each customer's oligos are made with the purity and quantity they require.

02/21/2024

Join us at OPT Congress March 13-14 in Boston, Massachusetts.

02/16/2024

Exciting industry news: GSK takes up option to secure nonexclusive license to Elsie's discovery platform for oligonucleotide drug discovery research.

https://www.fiercebiotech.com/biotech/gsk-still-has-crush-oligonucleotides-seals-deal-elsie

02/13/2024

We are thankful for the incredible women who help make Oligo Factory a success and push the boundaries of what is possible to advance science.

02/08/2024

Excited to return to the Oligonucleotide and Peptide Therapeutics Congress ( ) in March to discuss how we can support your oligo program from discovery through preclinical studies, including our newly launched GMP capabilities.

Check out this video from last year's conference to learn more: https://www.youtube.com/watch?v=V09XQsV7sqM

www.optcongress.comOPT Congress is the premier conference for professionals involved in discovering and developing oligonucleotide therapeutics. Now in its 8...

01/26/2024

Our custom GMP oligos are produced at scale (25mg+), meeting the critical quality specifications of our customers and accelerating their projects with industry-leading turnaround time.

Click here to learn more about our GMP capabilities and speak to our team: https://oligofactory.com/services/gmp/

01/18/2024

We are excited to announce the appointment of Caitlin Lefroy as our new Vice President of Sales and Marketing.

Ms. Lefroy brings a wealth of experience and a proven track record in commercial leadership within the life sciences industry.

This announcement comes on the heels of Oligo Factory's recent achievement of GMP ICHQ7 compliance, underscoring our commitment to exceptional quality control and the needs of our customers.

01/04/2024

Do you have GMP oligo needs this year? Reach out to our GMP oligo specialists today. We produce a range of custom GMP oligos in our state-of-the-art facility in Holliston, MA, and ship all over the world. https://oligofactory.com/services/gmp/

01/03/2024

Oligo Factory is now GMP compliant! We produce a range of custom oligos at scale, including gRNAs, ASOs, natural and modified DNA/RNA, aptamers, siRNAs, and more.

Quality, customization, and customer service are at the heart of all we do, and today’s announcement reinforces our commitment to our customers to provide the best oligos at an affordable price.

Learn more: https://www.businesswire.com/news/home/20240103324975/en

12/18/2023

2023 was a tremendous year for Oligo Factory. 📅👏 Some highlights:

• Opened new state-of-the-art manufacturing facility

• Expanded our talented team

• Doubled customer growth

• Increased manufacturing capacity by 12x while maintaining industry-leading turnaroud time

• Prepared for cGMP and ISO 13485 compliance in 2024

We're excited for what the new year holds and are grateful to our customers, our talented team, and our investors for helping us achieve so much this year.

12/15/2023

Our oligos are in everything from groundbreaking research projects to promising discovery-phase work.

Our focus is on you and creating oligos that help you realize your vision.

If you need a reliable partner to synthesize oligos to your specifications, start a conversation today with one of our scientists. https://oligofactory.com/talk-to-a-scientist/

12/08/2023

The U.S. Food and Drug Administration approved the first gene editing treatment in history today. The new treatment will help tens of thousands of patients with sickle cell disease.

Gene editing is a powerful tool that new therapies and treatments will continue to leverage in the future. Oligonucleotides are a key ingredient in researching, developing, and producing CRISPR-based therapeutics. We are proud to serve customers doing important work in gene editing and are excited for what the future holds.

Read the full story: https://www.cnbc.com/2023/12/08/casgevy-first-crispr-gene-editing-treatment-approved-in-us.html

CNBC

Casgevy uses the Nobel Prize-winning technology CRISPR to treat sickle cell disease, a blood disorder that affects about 100,000 Americans.